Task Force 5: Clinical Considerations for Myocarditis and Selected Cardiovascular Conditions, Including Valvular Heart Disease
Athletes with myocarditis, pericarditis, valvular heart disease, and other acquired cardiovascular conditions require careful evaluation when considering competitive sports participation. This document outlines key clinical considerations, risk factors, and expert consensus, serving as the rationale for Section V of the recent AHA/ACC Scientific Statement: Clinical Considerations for Competitive Sports Participation for Athletes with Cardiovascular Abnormalities. Disease-specific risk stratification and shared decision-making are essential in determining return-to-play eligibility. This Task Force document addresses myocarditis, pericarditis, the cardiovascular impact of respiratory viral infections, incidental myocardial fibrosis, Kawasaki disease, infiltrative cardiomyopathies, and valvular heart disease.
Authors
- James Sawalla Guseh (ORCID: https://orcid.org/0000-0003-0992-5635)
- Jonathan H. Kim (ORCID: https://orcid.org/0000-0001-5885-0284)
- Aaron Leigh Baggish (ORCID: https://orcid.org/0000-0003-2042-1489)
- Matthias Wilhelm (ORCID: https://orcid.org/0000-0003-4541-3995)
- SILVIA CASTELLETTI
- MATTHEW W. MARTINEZ
- BENJAMIN D. LEVINE
- LARRY A. ALLEN
Institutions
- University of Bern (CH)
- Emory University (US)
- Texas Health Dallas (US)
- University Hospital of Bern (CH)
- Centre Hospitalier Universitaire Vaudois (CH)
- Morristown Medical Center (US)
- Massachusetts General Hospital (US)
- IRCCS Istituto Auxologico Italiano (IT)
- Institute for Exercise and Environmental Medicine (US)
- University of Colorado Anschutz Medical Campus (US)
- Atlantic Health System (US)
- The University of Texas Southwestern Medical Center (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- Medicine & Science in Sports & Exercise
- Published
- 2026-11-13
- DOI
- https://doi.org/10.1249/mss.0000000000004093
- Primary Topic
- Cardiovascular Effects of Exercise
- Type
- article
- Field-Weighted Citation Impact
- 0.00